The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of 0.15 yuan per share, according to its 2021 financial results released late Monday.

Looking up: The company’s revenue tripled to 2.1 billion yuan last year, mainly due to the rapid growth of its drug-related contract research organization (CRO) business, whose turnover jumped 68.7% to 740 million yuan. Its revenue also got a boost from its recent acquisition of the pharmaceutical business of Zhejiang Langhua.

Take Note: Viva’s selling and administrative expenses increased by 618% and 116%, respectively, last year, mainly due to expanding its sales team and accelerating office space construction to meet its fast-growing business needs.

Digging Deeper: Founded in 2008 and listed in Hong Kong in 2019, Viva Biotech provides drug discovery services to global biotech and pharmaceutical customers for preclinical innovation drug development. It announced a positive profit forecast in early March, expecting a net profit of at least 280 million yuan last year, the first profit since its IPO. The company credited its improved performance mainly to the expansion of its business scope from front-end drug discovery to also include the contract development and manufacturing organization (CDMO) business for third-party clients, allowing it to become an integrated platform for drug research, development and production.

Market Reaction: After opening slightly lower on Tuesday morning, Viva Biotech’s shares rose as much as 4.2% before closing up by a milder 0.3% at HK$3.12 at the midday break. The stock has been on an uptrend since mid-March, rising 30% since then. But it still trades at the low end of its 52-week price range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…

NEWS WRAP: Nayuki pours up first annual profit

The premium tea chain aims to expand through franchising to boost its growth amid intense competition  By Teri Yu  Premium tea seller Nayuki Holdings Ltd. (2150.HK) on Wednesday reported its first annual profit since…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…